Stifel Nicolaus analyst Dylan Van Haaften has maintained their bullish stance on STMN stock, giving a Buy rating today.
Dylan Van Haaften’s rating is based on a combination of factors that highlight Straumann Holding AG’s potential for growth despite some macroeconomic challenges. The company is expected to achieve an 8.6% organic sales growth for the first quarter of 2025, driven by strong performance in the EMEA and APAC regions, which supports confidence in meeting the high single-digit growth guidance for the fiscal year. Although the US market presents some volatility, the company’s strategic initiatives, such as the Sprintray MIDAS deal and advancements in product offerings like iEXCEL, are seen as positive steps toward maintaining market share and achieving growth targets.
Despite a reduction in the price target from CHF150 to CHF140, the Buy rating is maintained as Straumann is anticipated to outperform in the dental implantology sector. The company’s ability to navigate macroeconomic headwinds and leverage its innovative product pipeline, coupled with expected easing in comparisons in the latter half of the year, positions it favorably for continued success. Additionally, the potential for market share gains and a compelling valuation at a near multi-year low multiple further support the Buy recommendation.
In another report released today, Barclays also maintained a Buy rating on the stock with a CHF148.00 price target.